Home | About | RSS Feed | Contact and Publicity Guidelines | Comment Policy the Law, the Universe, and Everything 


advertise-here4


Slip Opinions


Denial of tenure case at Georgetown raises thorny issues .  LAC

NYT editorial quotes Dan Solove likening NSA snooping to Seurat art: one small dot seems trivial, but together a portrait emerges. Here. (LAC)

Warren Buffett never negotiates on price, always makes his highest offer first.  LAC

An elite decline? (kw)

Unanswered Questions (kw)

Most under-appreciated thing about Warren Buffett: he built Berkshire to last well beyond him.  (LAC, at BRK annual meeting via Motley Fool, here.)

University governance as a new topic of public discussion.

An unusual profile of Mary Anne Franks (kw)

Aggressive copyright litigation run amok. (fp)

USA Today's Matt Krantz quoting me on Warren Buffett joining Twitter.  (LAC)


Our Podcast

Subscribe to Law Talk


  • Posts by Author

  • Categories

  • Archives


  • Recent Comments


    • George Conk on Unintended Consequences of Scholarship

    • Tyrone Grandison on Views on Surveillance May Depend on Degree of Responsibility

    • Katie Eyer on Sole Motives and University of Texas Southwestern Medical Center v. Nassar

    • Brian Clarke on Sole Motives and University of Texas Southwestern Medical Center v. Nassar

    • Douglas Levene on Sherrilyn Ifill on Race v. Class: The False Dichotomy

    • Howard Gilbert on The state secrets privilege in challenges to government surveillance programs

    • AF on The Humble Justice Scalia

    • Joe on Sherrilyn Ifill on Race v. Class: The False Dichotomy

    • prometheefeu on Sherrilyn Ifill on Race v. Class: The False Dichotomy

    • prometheefeu on Sherrilyn Ifill on Race v. Class: The False Dichotomy

    • Douglas Levene on Sherrilyn Ifill on Race v. Class: The False Dichotomy

    • Terri Holley on Call for Papers: National Business Law Scholars Conference

    • Joe on Sherrilyn Ifill on Race v. Class: The False Dichotomy

    • Joe on Sherrilyn Ifill on Race v. Class: The False Dichotomy

    • Shag from Brookline on Sherrilyn Ifill on Race v. Class: The False Dichotomy
  •  

    Site Meter

    About the Blog

    Concurring Opinions is a multiple authored, general interest legal blog.

    (Image: Wikicommons)

3D Patent Legislation

posted by Gerard Magliocca

Deven and I will discuss our 3D printing research at a conference this weekend.  To me, the most interesting legal issue for 3D printing is how Congress will react to this technology.  There are three broad principles that ought to shape any legislative response.

1.  Removing the shadow of liability:  Under current law, anybody who prints a patented item or uploads a 3D file that could allow such printing would be liable for infringement.  There is no fair use exception in patent and strict liability is the standard.  While an infringement lawsuit against a given individual is unlikely, the fact that liability is possible could chill a lot of useful research and tinkering.  Congress needs to do something about this.  One approach, which was proposed in the 19th century, would be to establish a fairly high jurisdictional minimum for damages to give a court the authority to hear a patent infringement case.  This would have the effect of excluding home 3D printing without disrupting other parts of the patent regulatory scheme.

2.  Product Safety:  A valid concern about some 3D printed products is that they will cause injuries because they will not be subject to rigorous testing.  Product liability law can handle this problem after the fact, but what about ex ante?  Congress could respond by creating an agency that would promulgate safety guidelines to address this concern.  Another facet of the public safety debate, of course, involves the 3D printing of guns or weapons. That also needs to be addressed, though in practice this will be really challenging.

3.  Standardization:  One advantage of 3D printing is that it allows for almost infinite customization, but on the other hand parts often need to fit within an existing product or network to function.  In other words, some standardization is necessary for optimal performance in some industries. Should this be left to the market?  (People who make subpar parts will just not make money) Should Congress impose minimal standards in certain areas and restrict 3D printing in those narrowly tailored fields?  That’s less clear to me.

One final note.  Valid regulation of safety and the imposition of standards SHOULD NOT become an excuse used by vested interests in the 2D patent system to stop the proliferation of 3D printing technology.


 February 22, 2013 at 9:44 am   Posted in: Intellectual Property, Uncategorized   Print This Post Print This Post

Responses (21)

  1. AndyK - February 22, 2013 at 9:52 am

    With respect to (2), it’s also worrying, things of this nature; http://legalnewsline.com/issues/big-pharma/239717-brand-name-drug-makers-ask-ala-sc-to-rehear-case-over-innovator-liability.

    Courts need to be careful not to fashion rules that will attach product liability to patentees when folks 3D print those (let’s say) devices and someone gets hurt.

  2. Shag from Brookline - February 22, 2013 at 10:22 am

    3D or not 3D, is that the question? Gun nuts may assert the Second Amendment in the manner of Hamlet:

    “Whether ’tis nobler in the mind to suffer
    The slings and arrows of outrageous fortune,
    Or to take arms against a sea of troubles
    And by opposing end them. ”

    in addressing concerns noted in point 2 of the post..

  3. prometheefeu - February 22, 2013 at 10:29 am

    AndyK,

    The article you linked to does not speak of creating liability for patentees. Here, Pfizer is alleged to have breached a duty to inform doctors of the side-effects of the product it sells. It seems pretty clear that merely holding the patent would not cause liability to attach. The only weird thing here is that the person suing purchased another identical product. But if Pfizer wanted to free itself of that liability, it could stop producing the drug. It is a little weird that the presence of the generic version in effect multiplies Pfizer’s liability, but it is inaccurate to say that it is Pfizer as a patentee that is liable.

  4. Richard - February 22, 2013 at 10:41 am

    Just came across your blog and found it really interesting. I have just started a blog with a colleague and are looking for inspiration – keep up the good work – cheers!

    Richard

  5. A.J. Sutter - February 22, 2013 at 11:11 am

    With respect to (1), what’s new about “the fact that liability is possible could chill a lot of useful research and tinkering”? Hasn’t that been the case prior to the spread of 3D printing as well?

    And given the safety concerns you mention in (2), might the chilling effect actually be a good thing? Or is the post’s last sentence actually intended to be read as if the clause “used by vested interests in the 2D patent system” were stricken? Would safety concerns categorically not be a valid reason to limit the spread of the technology? Would you prefer to regulate safety by limiting the availability of fair use/de minimis infringement exemptions? Or do you take the Milton Friedman position, of leaving safety issues to the market?

    More broadly, why have a bias in favor of the proliferation of the technology at all? How about a more precautionary approach, whereby the technology’s release is heavily regulated at first, until we can get a better handle on what kinds of social problems it raises? I realize that this bias is widely shared, and is aggressively promoted by Cass Sunstein and others, but it ought to be questioned. (Cf., e.g., Douglas Kysar’s eloquent defense of the precautionary principle in the environmental context.)

    (BTW, what is the “2D patent system” — isn’t this a misplaced modifier? There are plenty of patents on 3D things already, and I don’t expect the PTO is going to start sculpting the patents it issues, as opposed to issuing paper versions of them, anytime soon.)

  6. AF - February 22, 2013 at 1:04 pm

    Like AJ Sutter, I’m not understanding the novel issue here. Why do you anticipate that 3D printing will bring on a groundswell of socially beneficial patent infringement beyond what currently exists?

  7. Gerard - February 22, 2013 at 1:22 pm

    Well, I could turn the question around and ask why you think it won’t? The VCR and digital distribution of music examples, I submit, support my view.

  8. AF - February 22, 2013 at 2:55 pm

    Professor Magliocca, that is one of the stranger attempts at burden-shifting I have ever seen. Is the idea that all technological innovations are presumptively likely to upend patent law and require a legislative response? If not the burden would seem to be on you to explain why 3D printing is likely to do so.

    Your reference to VCRs and digital distribution suggests that you see 3D printing’s impact on patent law as analogous to the digital revolution’s impact on copyright law. I don’t think the analogy holds for a variety of reasons, eg, that the portion of 3-dimensional objects that are patent-protected is far lower than the portion of digital content that is subject to copyright; and, even more fundamentally, that 3D printers seem far less capable of producing serviceable copies of patented products than VCRs and computers are of producing acceptable copies of movies and music (anyone interested in a 3D-printed iphone? Segway? Lipitor pill?)

    What would be an example of a product currently under patent protection that could be replaced by a 3D printer in the foreseeable future?

  9. Gerard Magliocca - February 22, 2013 at 4:12 pm

    Well, it’s fine to say that no legislative response is necessary now. The paper is an attempt to lay down some markers for the future. If 3D printing turns out to be a bust, then no harm is done.

    Plenty of people, I think, are going to want 3D printed pills someday, especially if they can’t easily get to a pharmacy and need medicine. You may not trust them, but then again many people are still skeptical of buying things on Amazon.

  10. AF - February 22, 2013 at 5:35 pm

    How in the world would a 3D printer facilitate the creation of patented pharmaceuticals? What raw material would be used? Are these printers going to double as state-of-the-art chemistry labs? Even if they were, patent law would hardly be their biggest obstacle. Any company that distributed the raw materials for 3D-printed medicines (patented or unpatented) would get a very quick visit from the FDA.

    I can’t imagine how 3D printing technology could be used for anything besides relatively simple mechanical products; the manufacture of other products (chemical, electronic, biological, etc.) requires much more than effectively fabricating 3-dimensional shapes. And there just aren’t that many relatively simple mechanical products that are under patent. Certain medical devices and components I guess. But it’s very hard to imagine widespread patent infringement.

    If anything, 3D printing seems to raise more significant copyright, trademark, and trade dress issues than it does patent issues.

  11. AW - February 23, 2013 at 3:25 am

    Hi there,

    wondering whether this paper has been published already, would love to read a bit more about this.

    Thanks! Keep it going.

  12. Brett Bellmore - February 23, 2013 at 8:37 pm

    “How in the world would a 3D printer facilitate the creation of patented pharmaceuticals?”

    I suppose the idea is that 3d printers could eventually become something like Drexlerian nano-factories, in the same manner adding machines eventually became desktop computers. Increasing in power and versatility until they were capable of producing arbitrary molecular structures. It’s not entirely infeasible.

  13. AF - February 24, 2013 at 10:35 am

    Fair enough, Brett Bellmore, but that’s science fiction. Nothing like that is on the horizon.

  14. Brett Bellmore - February 24, 2013 at 2:30 pm

    Science fiction

    A lot of pharmaceuticals, some of them quite illegal, are not all that complex in their synthesis. An automated chem lab capable of churning out single dose amounts in a matter of hours does not strike me as infeasible. Probably end up regulated up the wazoo, though.

  15. Shag from Brookline - February 24, 2013 at 3:16 pm

    Brett’s “meth-odd” goes beyond sci-fi based upon his claim of non-infeasibility. (How about a chorus of “Nothing’s Impossible.”)

  16. AF - February 25, 2013 at 1:29 pm

    Brett: The fact that you can use 3D printers loaded with silicone-based sealant to print custom labware hardly suggests that the technology will exist in the foreseeable future to print patented drugs — ie, drugs discovered within the past 20 years — more cheaply than buying them.

    I agree that the printing of pharmaceuticals that are “not all that complex in their synthesis” is easier to imagine. However, few such pharmaceuticals are patented. And as you suggest, this sort of technology will butt up against pharmaceutical regulations long before it runs into patent law.

  17. A.J. Sutter - February 25, 2013 at 10:13 pm

    I’m happy to be corrected by a chemical engineer, but I think the pharmaceuticals are a distraction here. One needs to distinguish among fabrication processes. Printing is a deposition process, and deposition per se doesn’t involve any chemical changes. There may be some simple chemical changes that can be initiated by using a light source, such as the “curing” of certain polymer resins; but even there, the same light source won’t necessarily work for all resins. Granted that there may be ways to print successive layers of substances that chemically interact in a safe and controllable way; but in general, the chemical synthesis of a complex molecule from simpler materials may require many different steps, using a variety of catalysts, other reagents, and physical conditions (temperature, pressure, etc.). Different chemical bonds often need quite different conditions in order to form — chemistry isn’t like Drexlerian TinkerToys.

    This is especially true of pharmaceuticals, which often include rings with bonds that aren’t so easy to form. E.g., compare the simple structure of methaphetamine to the more complicated structures of Lipitor or LSD.Plus, forming bonds isn’t enough — you often need to get a particular stereoisomer for the molecules to have the desired effect. Only one of the 2 forms of meth (the link shows a version with a carbon coming out of the page; there’s also a form where that carbon sticks out behind the page) and only one of the 4 stereoisomers of LSD are psychoactive. Even if ingesting an unpurified mixture of the forms of a particular drug doesn’t have worse health consequences than ingesting the purified form, that isn’t true for all pharmaceuticals. (Actually, illegal meth is usually a mixture, and I’m not sure that it is so benign.) I doubt that 3D printing is the right way to characterize this, nor does it seem likely that the 3D printers to be commercialized will include such sophisticated and multi-product chemical reactors and product purification means.

  18. A.J. Sutter - February 25, 2013 at 10:41 pm

    Correction: the L-enantiomer of methamphetamine is an over-the-counter nasal decongestant, so racemic meth (a mix of the L- and D-forms, the latter being the stimulant) doesn’t seem to be radically worse for health than the pure D-form.

  19. Brett Bellmore - February 26, 2013 at 6:48 pm

    AF, while there currently isn’t any desktop appliance that will take simple chemicals, and output complex ones under software control, there certainly trends in that direction. Polypeptide synthesis, DNA synthesis, “lab on a chip systems”, they likely will converge in time to produce such an appliance.

    And while no desktop machine is going to manufacture any given chemical more cheaply than a dedicated factory, there are already plenty of drugs which can be manufactured on a small scale more cheaply than they’re *sold*; Why, when I went through chemo a few years ago, one of the drugs cost so much I could have tooled up the synthesize it for the cost of a couple doses.

    Not that I was being robbed, I understand quite well that each successful drug must carry the load for many drugs which failed to reach the market.

    But it has to be understood that, while synthesizing novel chemical structures requires a fair amount of intelligence, following a cookbook recipe for an old structure is well within the capacity of robotics. It’s only a matter of time before chemical fabbers join 3d printers.

    The legal obstacles will be bigger than the technical ones.

  20. AF - February 27, 2013 at 1:17 pm

    Brett, I’ll defer to you on how far we are away from desktop drug manufacturing. But for unskilled consumers to be able to manufacture a particular drug (or any other complex technology) at home, someone with skill in the technological field is going to have to provide software and kits of raw materials that are specifically designed to allow consumers to create that product. Creating complex technology “from scratch” at home using general purpose machinery and materials, even with the benefit of a “cookbook,” takes a level skill and dedication that is always going to be relatively rare in the general population.

    From the perspective of patent law, the possibility that skilled technologists will be able to recreate patented technology at lower cost than the monopoly prices charged by patent-holders or to distribute products that allow consumers to do so (which would be inducement of infringement), doesn’t strike me as a particularly novel or difficult problem. The whole point of patent law is to provide inventors with legal protection against such technologically-feasible competition. I suppose the use of software could change things a little given how easy it is to distribute, but you would still need someone to write a specific program for each patented product, knowing that doing so constitutes inducement of patent infringement (and therefore that there is no money in it), and consumers would still have to go out and find the raw materials, which, even if commercially available, are unlikely to be particularly easy or simple to procure for the average consumer. It doesn’t strike me as something that’s going to happen on anything like the scale as digital-music downloading.

  21. Shag from Brookline - February 27, 2013 at 1:25 pm

    Can a 3D printer compete with a table-top still producing my drug of choice?

Leave a Reply

Spam protection by WP Captcha-Free


  • « Previous post
  • Next post »

Authors

Daniel J. Solove
Kaimipono Wenger
Dave Hoffman
Frank Pasquale
Deven Desai
Danielle Citron
Lawrence Cunningham
Sarah Waldeck
Jaya Ramji-Nogales
Solangel Maldonado
Gerard Magliocca

Guests

Kelli A. Alces
Andrew Blair-Stanek
Ryan Calo
Katie Eyer
Stephen Galoob
Woodrow Hartzog
Claire Hill
William McGeveran
David L. Schwartz
Babak Siavoshy
Charles K. Whitehead
Aaron Zelinsky


















Previous Guests

Michael Abramowicz
Michelle Adams
Robert Ahdieh
Marvin Ammori
Michelle Anderson
Laura Appleman
Derek Bambauer
Taunya Lovell Banks
Ann Bartow
Steven Bellovin
Adam Benforado
Gaia Bernstein
Francesca Bignami
Josh Blackman
Joseph Blocher
Jeremy Blumenthal
Kathleen Boozang
Bruce Boyden
Donald Braman
Khiara Bridges
Al Brophy
Neil H. Buchanan
Bill Burke-White
Scott Burris
Paul Butler
Ryan Calo
Naomi Cahn
Anupam Chander
Miriam Cherry
Jack Chin
Glenn Cohen
Gabriella Coleman
Jennifer Collins
Caroline Mala Corbin
Thomas Crocker
andré douglas pond cummings
Allison Danner
Laura DeNardis
Brannon Denning
Deven Desai
Mike Dimino
Mark Edwards
Maxine Eichner
Jessica Erickson
David Fagundes
Lisa Fairfax
Joshua Fairfield
Christine Haight Farley
Kim Ferzan
Dan Filler
Mary Anne Franks
Susan Freiwald
Michael Froomkin
Amanda Frost
Brian Frye
Timothy Glynn
Rachel Godsil
Eric Goldman
Kyle Graham
David Gray
Craig Green
Tristin Green
Jonathan Hafetz
Vivian E. Hamilton
Meredith Harbach
Michelle Harner
Angela Harris
Jeffrey Harrison
Hosea Harvey
Erica Hashimoto
Jennifer Hendricks
Carissa Hessick
Laura Heymann
Robert Hillman
Gilbert A. Holmes
Nicole Huberfeld
Christine Hurt
Darian Ibrahim
Sherrilyn Ifill
John Ip
Shavar Jeffries
Kevin Johnson
Kristin Johnson
Jeff Jonas
Courtney Joslin
Dan Kahan
Jeffrey Kahn
Brian Kalt
Sam Kamin
Michael Kang
Chimène Keitner
Alicia Kelly
Orin Kerr
Jay Kesten
Nancy Kim
Heidi Kitrosser
Adam Kolber
Russell Korobkin
Alex Kreit
Anita S. Krishnakumar
Susan Kuo
Greg Lastowka
Sarah Lawsky
Youngjae Lee
Margaret Lewis
Erik Lillquist
Jeff Lipshaw
Jonathan Lipson
Jacqueline Lipton
Matthew Lister
Joseph Liu
Michael Madison
Tayyab Mahmud
Kevin Noble Maillard
Solangel Maldonado
Jason Mazzone
Linda McClain
William McGeveran
Salil Mehra
Carrie Menkel-Meadow
Max Minzner
Viva Moffat
Scott Moss
Eric Muller
Janai Nelson
Jaya Ramji-Nogales
Helen Norton
Elizabeth Nowicki
Paul Ohm
Angela Onwuachi-Willing
David Opderback
David Orentlicher
Michael O'Shea
Kristen Osenga
Mary-Rose Papandrea
Rafael Pardo
Marcy Peek
Eduardo Peñalver
Robert Percival
Michael J. Pitts
Marc Poirier
David Post
Amanda Pustilnik
Shruti Rana
Geoffrey Rapp
Meredith Render
William Reynolds
Neil Richards
Lori Ringhand
Alice Ristroph
Marc Roark
Brishen Rogers
Sasha Romanosky
Aaron Saiger
Tuan Samahon
Susan Scafidi
David Schleicher
David Schraub
Paul Secunda
Lea Shaver
Jonathan Siegel
Jessica Silbey
Peter Smith
Judd Sneirson
Adam Steinman
Charles Sullivan
Rick Swedloff
Peter Swire
Olivier Sylvain
Steph Tai
Andrew Taslitz
Robert Tsai
Jenia Turner
Joseph Turow
Steve Vladeck
Ari Waldman
Spencer Weber Waller
Howard Wasserman
Melissa Waters
Elizabeth A. Wilson
Frank Wu
Alfred Yen
Corey Yung
David Zaring
Timothy Zick
Michael Zimmer
Jonathan Zittrain

Ownership

Concurring Opinions is a
general-interest legal blog
operated by Concurring
Opinions LLC, a Pennsylvania
Limited Liability Corporation.

Blogroll

Above the Law
Access to Justice
ACS Blog
Althouse
Balkinization
Becker-Posner Blog
BlackProf
BoingBoing
Chicago Law Faculty Blog
Conglomerate
CrimLaw
Crime & Federalism
CrimProf Blog
Crooked Timber
Derechoalderecho
Discourse.net
Dorf on Law
Election Law
Emergent Chaos
The Faculty Lounge
Feminist Law Profs
43(B)log
Freakonomics Blog
Freedom to Tinker
Google Blogoscoped
How Appealing
Ideoblog
Info/Law
Instapundit.com
Juris Novus
Jurisdynamics
Just Books
Law and Humanities Blog
Law and Letters
Law Librarian Blog
Legal Profession Blog
Legal Theory Blog
Legal Times Blog
Leiter Reports
Brian Leiter's Law School Reports
Lessig Blog
Madisonian Theory
Media Law Blog
Mirror of Justice
The Moderate Voice
National Security Advisors
Opinio Juris
Point of Law
PrawfsBlawg
Privacy and Security Training
ProfessorBainbridge.com
Property Prof Blog
Red Tape Chronicles
The Right Coast
Schneier on Security
SCOTUSBlog
Security Dilemmas
Sentencing Law and Policy
Simple Justice
Sivacracy.net
The Situationist
Susan Crawford
TalkLeft
Talking Points Memo
TaxProf Blog
TeachPrivacy Blog
Tech & Marketing Law
Truth on the Market
Volokh Conspiracy
WorkPlace Prof Blog
WSJ Law Blog
Wonkette
The Yin Blog


© Concurring Opinions

Powered by WordPress